Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study.

Sheehan DV, Croft HA, Gossen ER, Levitt RJ, Brullé C, Bouchard S, Rozova A.

Psychiatry (Edgmont). 2009 May;6(5):20-33.

2.

Efficacy and safety of prolonged-release trazodone in major depressive disorder: a multicenter, randomized, double-blind, flexible-dose trial.

Zhang L, Xie WW, Li LH, Zhang HG, Wang G, Chen DC, Cao Y, Cui LJ, Zhang KR, Shi JG, Tan QR, Zheng HB, Xu XF, Cheng ZH, Zhao JP.

Pharmacology. 2014;94(5-6):199-206. doi: 10.1159/000368559. Epub 2014 Nov 5.

PMID:
25376160
3.

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.

Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70.

PMID:
15589385
4.
5.

Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial.

Tran P, Skolnick P, Czobor P, Huang NY, Bradshaw M, McKinney A, Fava M.

J Psychiatr Res. 2012 Jan;46(1):64-71. doi: 10.1016/j.jpsychires.2011.09.003. Epub 2011 Sep 16.

6.
7.

Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.

Asnis GM, Bose A, Gommoll CP, Chen C, Greenberg WM.

J Clin Psychiatry. 2013 Mar;74(3):242-8. doi: 10.4088/JCP.12m08197.

8.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
10.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
11.

Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder.

Katila H, Mezhebovsky I, Mulroy A, Berggren L, Eriksson H, Earley W, Datto C.

Am J Geriatr Psychiatry. 2013 Aug;21(8):769-84. doi: 10.1016/j.jagp.2013.01.010. Epub 2013 Feb 6.

PMID:
23567397
12.

A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.

Munizza C, Olivieri L, Di Loreto G, Dionisio P.

Curr Med Res Opin. 2006 Sep;22(9):1703-13.

PMID:
16968574
13.

Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study.

Bielski RJ, Cunningham L, Horrigan JP, Londborg PD, Smith WT, Weiss K.

J Clin Psychiatry. 2008 Apr;69(4):571-7.

PMID:
18373383
14.

Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.

Davis R, Wilde MI.

CNS Drugs. 1996 May;5(5):389-402. doi: 10.2165/00023210-199605050-00007.

PMID:
26071050
15.

A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.

Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, Ciccone P.

J Clin Psychopharmacol. 2006 Dec;26(6):653-6.

PMID:
17110825
16.
17.

[Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].

Olié JP, Gourion D, Montagne A, Rostin M, Poirier MF.

Encephale. 2009 Dec;35(6):595-604. doi: 10.1016/j.encep.2009.10.011. French.

PMID:
20004291
18.

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW.

J Clin Psychopharmacol. 2008 Dec;28(6):631-7. doi: 10.1097/JCP.0b013e31818a6cea.

PMID:
19011431
19.
20.

Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression.

Ravindran AV, Guelfi JD, Lane RM, Cassano GB.

J Clin Psychiatry. 2000 Nov;61(11):821-7.

PMID:
11105734

Supplemental Content

Support Center